20-80 yo KL≧II osteoarthritis patients
VAS≧4, BMI 18-35 OA patients
Complete cervical/thoracic SCI (ASIA A/B)
Post-injury 1-12 months with normal renal/hepatic function
China Medical University Hospital uses autologous bone marrow mesenchymal stem cells (BM-MSCs) to treat two difficult diseases: knee osteoarthritis (KOA) and spinal cord injury (SCI). Knee treatment uses intra-articular injection with two doses per course (5×10⁷ cells/2ml) at 6-8 week intervals, unilateral or bilateral. SCI treatment uses intrathecal multi-dose injection combined with advanced MRI/fMRI imaging for quantitative assessment. Clinical data shows significant VAS and WOMAC improvement at 9 weeks, sustained to 12 months; MRI T2 mapping shows improved cartilage water content. KOA: 54 patients, 90 knees, zero SAE. SCI: 57.14% (4/7) ISNCSCI motor improvement (vs Korean trial 12.5%). One of few Taiwan teams with both indications, outperforming Spain, Australia, Korea benchmarks.
Autologous BM-MSCs, low immune rejection
High-cell-count multi-dose injection strategy
Advanced MRI T2 mapping quantitative assessment
Spinal/cerebral functional imaging for SCI
Both KOA and SCI indications
Few Taiwan teams with both indications
KOA (Knee Osteoarthritis) Service DataConsultation & Clinic Volume: [Awaiting your specific numbers]Enrollment & Screening: Successfully signed and enrolled 65 cases. Treatment & Completion: 56 cases (totaling 90 knees) entered and completed the full stem cell injection protocol. National Market Share: Autologous BM-MSC cases treated at CMUH account for up to 78% of the national total.
SCI (Spinal Cord Injury) Service DataConsultation & Clinic Volume: [Awaiting your specific numbers]Enrollment & Treatment: Successfully signed 11 cases, with 7 cases having undergone stem cell therapy. Completion Progress: 6 cases have successfully completed the entire cell therapy protocol.
KOA: 100% completion rate.
KOA: 100% execution rate.
KOA: 78% national market share.
KOA: Significant pain relief at 12 months.
SCI: 85.7% execution rate.
SCI: 1 case progressed from AIS Grade A to C. Safety: 0% infection rate.
Safety: 0 cases of serious adverse events (SAEs). Satisfaction: Overall patient satisfaction exceeds 98%.
KOA infection rate is 0%
SCI infection rate is 0%
serious adverse events :0
KOA adverse event rate is 7%
SCI adverse event rate is 0%
Satisfaction: >98%
Word-of-Mouth: Strong patient-to-patient recommendations
Non-Surgical Relief: Achieved pain mitigation without surgery
Quality of Life: Restored patients' daily living quality
Outperforms Korean Neurosurgery SCI trial
Better than Australia Freitag MOAKS team
Better than Spain Lamo-Espinosa WOMAC team
Advanced MRI assessment beyond traditional
Manuscripts ready for journal submission
Invited speaker at international stem cell forums
Provides alternative to knee surgery
Offers regenerative option for SCI patients
Precision imaging enhances evidence level
Foundation for future stem cell tendon/nerve reconstruction
Advances domestic regenerative medicine industry
